Hideki Arima

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Stereoselectivity of a potent calcium antagonist, 1-benzyl-3-pyrrolidinyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Kazuharu Tamazawa, Hideki Arima, Tadao Kojima et al. · Journal of Medicinal Chemistry · 1986 · 86 citations · Full text

Pharmaceutical Science, X Hbr, Organic Chemistry +16

Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: <scp>VENUS</scp> ‐ <scp>PC</scp> study

Nobuaki Suzuki, Shoichi Hazama, Haruo Iguchi et al. · Cancer Science · 2016 · 63 citations · Full text

Imidazo[2,1-b]benzothiazoles. 2. New immunosuppressive agents

Toshiyasu Mase, Hideki Arima, K. Tomioka et al. · Journal of Medicinal Chemistry · 1986 · 58 citations

Immunological Activities, Medicinal Chemistry, Allergy +13

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara et al. · Multiple Sclerosis and Related Disorders · 2020 · 37 citations · Full text